| Literature DB >> 26108791 |
Masanori Ono1, Takashi Kajitani1, Hiroshi Uchida1, Toru Arase1, Hideyuki Oda1, Sayaka Uchida1, Kuniaki Ota1, Takashi Nagashima1, Hirotaka Masuda1, Kaoru Miyazaki1, Hironori Asada1, Naoko Hida1, Yo Mabuchi2, Satoru Morikawa2, Mamoru Ito3, Serdar E Bulun4, Hideyuki Okano2, Yumi Matsuzaki2, Yasunori Yoshimura1, Tetsuo Maruyama5.
Abstract
Repeated and dramatic pregnancy-induced uterine enlargement and remodeling throughout reproductive life suggests the existence of uterine smooth muscle stem/progenitor cells. The aim of this study was to isolate and characterize stem/progenitor-like cells from human myometrium through identification of specific surface markers. We here identify CD49f and CD34 as markers to permit selection of the stem/progenitor cell-like population from human myometrium and show that human CD45(-) CD31(-) glycophorin A(-) and CD49f(+) CD34(+) myometrial cells exhibit stem cell-like properties. These include side population phenotypes, an undifferentiated status, high colony-forming ability, multilineage differentiation into smooth muscle cells, osteoblasts, adipocytes, and chondrocytes, and in vivo myometrial tissue reconstitution following xenotransplantation. Furthermore, CD45(-) CD31(-) glycophorin A(-) and CD49f(+) CD34(+) myometrial cells proliferate under hypoxic conditions in vitro and, compared with the untreated nonpregnant myometrium, show greater expansion in the estrogen-treated nonpregnant myometrium and further in the pregnant myometrium in mice upon xenotransplantation. These results suggest that the newly identified myometrial stem/progenitor-like cells influenced by hypoxia and sex steroids may participate in pregnancy-induced uterine enlargement and remodeling, providing novel insights into human myometrial physiology.Entities:
Keywords: CD34; CD49f; myometrium; pregnancy; stem cells; uterus
Mesh:
Substances:
Year: 2015 PMID: 26108791 PMCID: PMC6058739 DOI: 10.1095/biolreprod.114.127126
Source DB: PubMed Journal: Biol Reprod ISSN: 0006-3363 Impact factor: 4.285
Fig. 1Isolation and characterization of the human myometrial DP/Lin− fraction. A) Flow cytometric profiles of Lin+ and Lin− fractions. Lin− cells were divided into four fractions (I–IV) based on the expression pattern of CD34 and CD49f. The proportion of each fraction as a percentage of total living cells is shown. B) Hoechst-staining profiles of Lin− populations subsequently sorted by their CD34 and CD49f staining intensities. The percentage of SP cells is 2.73% in fraction I, 0% in fraction II, 0.07% in fraction III, and 0.06% in fraction IV. C) Messenger RNA expression of genes in DP/Lin−, CD49f−/CD34+/Lin−, CD34−/Lin−, and whole myometrial tissues as determined by RT-PCR. Representative of five independent experiments. D) Cell proliferation activities of Lin+ and fractions I–IV of the Lin− population under normoxic and hypoxic conditions as determined by the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay. Each bar indicates the mean + SEM of the absorbance at 490 nm obtained from three independent experiments using three individual samples. *P < 0.05. E) Colony formation by a single sorted DP/Lin− cell after the indicated days of hypoxic culture. After seeding 200 cells/cm2, single sorted DP/Lin− cells attached to the culture dish 1 day (one d) after seeding. The cells then formed colonies after the indicated days of culture. Scratches in the culture dish serve to identify the field. Bar = 100 μm. F) Immunofluorescence of a colony generated from a single sorted DP/Lin− cell using 4′,6-diamidino-2-phenylindole dihydrochloride and an antibody against αSMA. Representative of five independent experiments. Bar = 100 μm. G) Colony formation potential of DP/Lin− under hypoxic conditions. Each bar indicates mean + SEM of the average colony number in 30 dishes for unfractionated myometrial cells and each indicated cell subpopulation obtained from five independent experiments. U, unfractionated myometrial cells. *P < 0.005 versus unfractionated myometrial cells; †P < 0.005 versus CD49f−/CD34+/Lin−; ‡P < 0.005 versus CD34−/Lin+.
List of antibodies used in this study.
| Antigen | Clone | Fluorochrome and isotype (usage) | Supplier |
|---|---|---|---|
| CD31 (FACS) | WM59 | PE-conjugated mouse IgG1 (20 μl/1 × 106 cells) | BD Biosciences (San Jose, CA) |
| CD45 (FACS) | HI30 | PE-conjugated mouse IgG1 (5 μl/1 × 106 cells) | BD Biosciences |
| Glycophorin (FACS) | GAR-2 | PE-conjugated mouse IgG2b (20 μl/1 × 106 cells) | BD Biosciences |
| CD49f (FACS) | GoH3 | FITC-conjugated rat IgG2a (20 μl/1 × 106 cells) | BD Biosciences |
| CD34 (FACS) | 581 | APC-conjugated mouse IgG1 (20 μl/1 × 106 cells) | BD Biosciences |
| Collagen type II | Polyclonal | Rabbit (1:50) | Quartett (Berlin, Germany) |
| α-Smooth muscle actin | 1A4 | Mouse IgG2a (1:100) | DAKO Cytomation (Glostrup, Denmark) |
| Human vimentin | V9 | Cy3-conjugated mouse IgG1 (1:200) | SIGMA Chemical (St. Louis, MO) |
| Oxytocin receptor | 2F8 | Mouse IgM (1:1000) | ROHTO Pharmaceutical (Osaka, Japan) |
FACS, fluorescence-activated cell sorting; PE, phycoerythrin; IgG, immunoglobulin G; FITC, fluorescein isothiocyanate; APC, allophycocyanin; IgM, immunoglobulin M.
List of primer sets used in this study.
| Gene name (symbol) | Primer sets | Accession no. |
|---|---|---|
| Estrogen receptor 1 (ER alpha) ( | 5′-ACAAGCGCCAGAGAGATGAT-3′ | NM_000125 |
| 5′-CAGATTCATCATGCGGAACC-3′ | ||
| Estrogen receptor 2 (ER beta) ( | 5′-GCCTTAATTCTCCTTCCTCC-3′ | NM_001214902 |
| 5′-TACATCCTTCACACGACCAG-3′ | ||
| Progesterone receptor ( | 5′-GACTGAGCTGAAGGCAAAGG-3′ | NM_000926 |
| 5′-TCCAAGACACTGTCCAGCAG-3′ | ||
| Calponin 1, basic, smooth muscle ( | 5′-AAGTATGACCACCAGCGGGAGCAG-3′ | NM_001299 |
| 5′-TAGGCGGAATTGTAGTAGTTGTGT-3′ | ||
| Smoothelin ( | 5′-GCTGAGGAGCTGATGACTAT-3′ | NM_134270 |
| 5′-TTGAGAAGCTGGAGAAGGAG-3′ | ||
| ATP-binding cassette, sub-family G (WHITE), member 2 ( | 5′-GGCCTCAGGAAGACTTATGT-3′ | NM_004827 |
| 5′-AAGGAGGTGGTGTAGCTGAT-3′ | ||
| Glyceraldehyde-3-phosphate dehydrogenase ( | 5′-TCACCATCTTCCAGGAGCG-3′ | NM_002046 |
| 5′-CTGCTTCACCACCTTCTTGA-3′ | ||
| Bone gamma-carboxyglutamate (gla) protein ( | 5′-ATGAGAGCCCTCACACTCCTC-3′ | NM_199173 |
| 5′-GCCGTAGAAGCGCCGATAGGC-3′ | ||
| Runt-related transcription factor 2 ( | 5′-GTGGACGAGGCAAGAGTTTCA-3′ | NM_004348 |
| 5′-TGGCAGGTAGGTGTGGTAGTG-3′ | ||
| Alkaline phosphatase, liver/bone/kidney ( | 5′-TGGAGCTTCAGAAGCTCAACACCA-3′ | NM_000478 |
| 5′-ATCTCGTTGTCTGAGTACCAGTCC-3′ | ||
| Collagen type I, alpha 2 ( | 5′-GGACACAATGGATTGCAAGG-3′ | NM_000089 |
| 5′-TAACCACTGCTCCACTCTGG-3′ | ||
| Integrin-binding sialoprotein ( | 5′-AATGAAAACGAAGAAAGCGAAG-3′ | NM_004967 |
| 5′-ATCATAGCCATCGTAGCCTTGT-3′ | ||
| Parathyroid hormone 1 receptor ( | 5′-AGGAACAGATCTTCCTGCTGCA-3′ | NM_000316 |
| 5′-TGCATGTGGATGTAGTTGCGCGT-3′ | ||
| Lipoprotein lipase ( | 5′-GAGATTTCTCTGTATGGCACC-3′ | NM_000237 |
| 5′-CTGCAAATGAGACACTTTCTC-3′ | ||
| Peroxisome proliferator-activated receptor gamma ( | 5′-GCTGTTATGGGTGAAACTCTG-3′ | NM_005037 |
| 5′-ATAAGGTGGAGATGCAGGCTC-3′ | ||
| Aggrecan ( | 5′-TGAGGAGGGCTGGAACAAGTACC-3′ | NM_001135 |
| 5′-GGAGGTGGTAATTGCAGGGAACA-3′ | ||
| Collagen, type II, alpha 1 ( | 5′-CAGGTCAAGATGGTC-3′ | NM_001844 |
| 5′-TGCAGCACCTGTCTCACCA-3′ | ||
| Endogenous retroviral sequence 3 ( | 5′-CATGGGAAGCAAGGGAACTAATG-3′ | NM_001007253 |
| 5′-CCCAGCGAGCAATACAGAATTT-3′ |
Fig. 2Multipotential differentiation of the DP/Lin− population. A) Osteoblast-differentiation capacity of the DP/Lin− population. Neither non-DP/Lin− nor Lin+ treated with (+) or without (−) osteoblast-inducing medium differentiated to the osteoblast lineage as determined by alkaline phosphatase staining and by RT-PCR for the expression of osteoblast lineage-specific genes. BGLAP, bone gamma-carboxyglutamate protein; RUNX2, runt-related transcription factor 2; ALPL, alkaline phosphatase, liver/bone/kidney; COL1A2, collagen type I, alpha 2; IBSP, integrin-binding sialoprotein; PTH1R, parathyroid hormone 1 receptor. Representative of three independent experiments. Bar = 50 μm. B) Adipocyte-differentiation capacity of DP/Lin− cells. Neither non-DP/Lin− nor Lin+ treated with (+) or without (−) adipocyte-inducing medium differentiated to the adipocyte lineage, as determined by Oil red-O staining and by RT-PCR for the expression of adipocyte lineage-specific genes. LPL, lipoprotein lipase; PPARG, peroxisome proliferator-activated receptor gamma. Representative of three independent experiments. Bar = 30 μm. C) Chondrocyte-differentiation capacity of DP/Lin- cells. Induction of chondrocyte differentiation of DP/Lin−, as determined by staining with toluidine blue or collagen type II and by RT-PCR for the expression of chondrocyte lineage-specific genes as indicated. ACAN, aggrecan; COL2A1, collagen, type II, alpha 1. Representative of three independent experiments. Bar = 50 μm.
Fig. 3In vivo reconstitution of human myometrial tissues from DP/Lin− cells in pregnant and nonpregnant uteri of NOG mice. A) Experimental design for in vivo transplantation analysis. B–E) Immunofluorescence and confocal microscopy of serial sections obtained from NOG mouse uteri transplanted with DP/Lin− (B, C, E) or non-DP/Lin− (D) that then received no further treatment (B), treatment with E2 (C, D), or mating (E). These sections were immunostained for αSMA, Vm, OTR, or with TOTO3. Representative of three independent experiments. Bars = 100 μm.
Fig. 4Quantification of human-derived cells in NOG mouse uteri. A) Quantification of human-derived cells in nonpregnant, E2-treated, or pregnant NOG mouse uteri xenotransplanted with DP/Lin−, non-DP/Lin−, or Lin+ using real-time PCR amplification for human ERV3 retroviruses. Each bar indicates the mean + SEM of the relative amount of ERV3 PCR products obtained from three independent experiments. *P < 0.05 versus DP/Lin− (Cx); †P < 0.05 versus DP/Lin− (E2). B) The uteri of ovariectomized NOG mice were transplanted with each indicated fraction, treated with or without one or two E2 pellets, excised 7 wk later, and subjected to real-time PCR amplification for human ERV3 retroviruses. Each bar indicates the mean + SEM of the relative amount of ERV3 PCR products obtained from three independent experiments. *P < 0.05 versus non-DP/Lin−(0); †P < 0.05 versus Lin+ (0); ‡P < 0.05 versus DP/Lin− (0); §P < 0.05 versus DP/Lin− (1).